All Articles

Reed's Q2 results show major operational gains and a shrinking net loss, but a steep sales decline and a looming cash crunch raise critical questions.

With a NYSE delisting notice and a dividend under scrutiny, Lument Finance Trust's Q2 report is more than just numbers—it's a test of its strategy.

SINTX Technologies is shifting from R&D to sales, but its ambitious med-tech goals are balanced by a precarious financial reality. Is this a blueprint for resilience?

With FDA clearance for its AI burn scanner, Spectral AI faces its next test: conquering the market. Can it turn government contracts into commercial success?

Black Rock Coffee Bar reports a stellar quarter with 25% revenue growth, but a deeper look reveals the complex challenges of rapid expansion in a competitive market.

With pivotal data imminent for two cancer drugs and a fortified balance sheet, SELLAS is at a crucial inflection point. Can it deliver on its promise?

NeuroPace reports strong Q2 growth and raises 2026 guidance, driven by its RNS system. A new AI tool and key clinical data signal a deeper push into personalized medicine.

BridgeBio Oncology is doubling down on a costly strategy, betting that combining its novel drugs is the key to defeating hard-to-treat RAS-driven cancers.

AGT Food and Ingredients' Q2 results signal a successful shift to higher-margin foods, with its packaged foods segment surging despite global headwinds.

A sharp revenue drop and net loss for IZEA masks a major strategic pivot. With $46M in cash, the company is betting its future on enterprise clients.

A pivotal ATF ruling reclassifies the BolaWrap as a restraint tool, not a weapon. This opens a vast private market, but as the tool expands beyond police, new questions of oversight arise.

While the dry bulk market is strong, Pangaea's Q2 earnings reveal a model where specialized fleets and integrated logistics deliver superior, market-beating margins.

Kodiak Sciences launches a pivotal trial for a new drug aiming to best current treatments for diabetic eye disease. Is this the future of vision care?

RBI will use cash on hand to repurchase 2.8M units from 3G Capital, a move set to boost EPS and signal a strategic recalibration by its largest shareholder.

A routine dividend from Genuine Parts Company offers a rare look into the financial health of the vast, physical network that keeps our world moving.

Matthews International appoints Michael Whitehead, a tech growth leader from Lincoln Electric, to navigate a portfolio transformation and reverse recent financial turbulence.

A Singapore data center operator is merging with a Silicon Valley AI startup, creating a new U.S.-based contender in the booming AI inference market.

abrdn's latest CEF distributions promise steady income, but a closer look reveals a complex web of 'return of capital' and managed policies. Here's what investors need to know.

Summit Midstream posts strong Q2 earnings, but a closer look reveals a strategic pivot, funding a Williston revival while grappling with declining assets.

As VolitionRx readies its Q2 update, investors and scientists look for proof that its pioneering epigenetic tests can translate into commercial success.